Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 24Colorectal Neoplasms 12Colonic Neoplasms 9Rectal Neoplasms 6Carcinoma, Hepatocellular 6Pancreatic Neoplasms 5Esophageal Squamous Cell Carcinoma 4Biliary Tract Neoplasms 4Gallbladder Neoplasms 3Esophageal Neoplasms 3HER2-positive Gastric Cancer 2Cholangiocarcinoma 2Stage IA Pancreatic Adenocarcinoma 1Recurrence 1Klatskin Tumor 1Immunotherapy 1Gastric Adenocarcinoma 1For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method 1Extrapancreatic Neuroendocrine Tumor 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Bile Duct Neoplasms 1Advanced Pancreatic Cancer 1Advanced Biliary Tract Carcinoma 1

Interventions

Trastuzumab 5Oxaliplatin 4Capecitabine 3trastuzumab deruxtecan 2tislelizumab 2disitamab vedotin 2Tegafur 2Fluorouracil 2Cisplatin 2tucatinib 1pembrolizumab 1S 1 (combination) 1Ramucirumab 1Paclitaxel 1HMPL-013 1Drug Therapy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
HER2-positive Gastric Cancer × Tegafur × Gastrointestinal × Clear all
NCT06439550 2024-06-03

Adjuvant Treatment With Serplulimab,Trastuzumab and SOX in the HER-2 Positive GC/GEJC

The First Affiliated Hospital of Zhengzhou University

Phase 2 Not yet recruiting
42 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT05070598 2021-10-07

Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer

Shengjing Hospital

Phase 2 Unknown
35 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡